计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C411992-100μg |
100μg |
现货 ![]() |
| |
| C411992-1mg |
1mg |
现货 ![]() |
| |
| C411992-5mg |
5mg |
现货 ![]() |
| |
| C411992-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Cetuximab (anti-EGFR), 表皮生长因子受体抗体 |
|---|---|
| 别名 | 西妥昔单抗 | EGFR抗体 | EGFR单克隆抗体 | EGFR药靶抗体 | ERBB1抗体 | ERBB1单克隆抗体 | ERBB1药靶抗体 |
| 英文别名 | C225 | Recombinant Cetuximab Antibody | Cetuximab (anti-EGFR) | Cetuximab (C225) | Anti-ERBB1 / EGFR / HER1 Reference Antibody (cetuximab) | Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody | Cell growth inhibiting protein 40 antibo |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 生化机理 | Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action. |
| 宿主种属 | 人(Human) |
| 特异性 | ERBB1/EGFR/HER1 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 表皮生长因子受体抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 28.4 kDa (Light Chain) & 53.4 kDa (Heavy Chain), under reducing conditions; 184.2 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 205923-56-4 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Cetuximab (anti-EGFR) (C411992) - Flow Cytometry
Flow Cytometry analysis of A431 cells labelling EGFR (red) with Cetuximab (anti-EGFR) (C411992). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Cetuximab (anti-EGFR) (C411992) - SEC
The purity of Cetuximab (anti-EGFR) (C411992) is more than 95% verified by HPLC.
Cetuximab (anti-EGFR) (C411992) - ELISA
Immobilized Human EGFR-Fc at 2 μg/mL can bind Cetuximab (anti-EGFR) (C411992) with the EC₅₀ of 10.67 ng/mL.
Cetuximab (anti-EGFR) (C411992) - ELISA
Immobilized Recombinant Human EGFR protein (rp176273) at 1.0 μg/mL can bind Cetuximab (anti-EGFR) (C411992) with the EC50 of 17.44 ng/mL.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | C411992 | |
| 分析证书 | C411992 | |
| 分析证书 | C411992 | |
| 分析证书 | C411992 | |
| 分析证书 | C411992 |
¥579.90
¥999.90
¥899.90
¥539.90
¥669.90
¥799.90
¥899.90
¥899.90
¥1,199.90
¥879.90
¥579.90
¥669.90
¥699.90
¥579.90
¥999.90
| 1. Liyin Wang, Milad Ashrafizadeh, Gautam Sethi, Xinjia Zhou. (2025) pH-responsive biomimetic zeolitic imidazolate framework-based nanoparticles for co-delivery of cetuximab and siRNA in synergistic therapy of laryngeal squamous cell carcinoma. Journal of Pharmaceutical Analysis, (101203). [10.1016/j.jpha.2025.101203] |